Products - Spinal conditions | Topic

Showing 12 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Risdiplam for treating spinal muscular atrophy (TA755)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
15 December 2023
Published:
16 December 2021
Tofacitinib for treating active ankylosing spondylitis (TA920)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 October 2023
Upadacitinib for treating active ankylosing spondylitis (TA829)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 September 2022
Nusinersen for treating spinal muscular atrophy (TA588)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 July 2019
Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures (TA279)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 April 2013
Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
12 November 2025
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Omaveloxolone for treating Friedreich’s ataxia in people 16 years and over ID6423
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Troriluzole for spinocerebellar ataxia [ID6456]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Neuro-Cells stem-cell treatment for traumatic spinal cord injury [TSID12048]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [ID6556]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [TSID12168]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

What we do

Into practice

Who we are

Spinal conditions Products

Showing 12 products

Risdiplam for treating spinal muscular atrophy (TA755)

Tofacitinib for treating active ankylosing spondylitis (TA920)

Upadacitinib for treating active ankylosing spondylitis (TA829)

Nusinersen for treating spinal muscular atrophy (TA588)

Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures (TA279)

Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]

Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089]

Omaveloxolone for treating Friedreich’s ataxia in people 16 years and over ID6423

Troriluzole for spinocerebellar ataxia [ID6456]

Neuro-Cells stem-cell treatment for traumatic spinal cord injury [TSID12048]

Onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [ID6556]

Onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [TSID12168]

Quality standards

Indicators

Get support from NICE

Learn how we evaluate technologies

Register your product

Find published and proposed evaluations

Our programmes

Get involved

What we do

Into practice

Who we are

Spinal conditions Products

Showing 12 products